Lobe Sciences Ltd.
LOBEF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.87M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $13.87 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-0.03 |
| Beta | 0.29 |
| Outstanding Shares | 277,748,003 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -2.18 |
|---|---|
| PEG | 4.73 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Next Earnings Call
Expected Date
December 28, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Lobe Sciences Ltd.
5 employees
CEO: Frederick Dominick Sancilio
Lobe Sciences Ltd. operates as a life sciences entity, primarily focused on the exploration and advancement of psychedelic pharmaceutical compounds. The company is actively engaged in formulating psilocybin-derived therapeutics, combined...